论文部分内容阅读
FLT3属于Ⅲ型受体酪氨酸激酶(RTK),是急性髓细胞性白血病(AML)最易发生突变的基因。近年来研究发现,FLT3基因的突变、过度表达与急性髓细胞性白血病的发生和预后评估密切相关,以FLT3突变作为靶点正在成为白血病治疗的一种新策略。同时,FLT3有可能为微小残留病的检测提供一种新
FLT3 belongs to type III receptor tyrosine kinase (RTK) and is the most frequently mutated gene in acute myeloid leukemia (AML). In recent years, the study found that FLT3 gene mutation, overexpression and acute myeloid leukemia is closely related to the occurrence and prognosis of FLT3 mutation as a target is becoming a new strategy for the treatment of leukemia. At the same time, FLT3 may provide a new test for the detection of minimal residual disease